A Phase 2/3, Randomized, Observer-Blind, Active-Controlled Study to Evaluate the Immunogenicity and Safety of S-268019 in Participants Aged 12 to 19 Years (COVID-19)

agata Tsutae0 个研究点目标入组 350 人开始时间: 2022年5月17日最近更新: 2023年10月17日

试验速览

暂无简介。

•Participant aged 12 to 19 years, at the time of signing the informed consent form (ICF).
•Male and female
•Capable of giving signed ICF from participants, minor participants and parent(s) or legal guardian as stated in the protcol, which includes compliance with the requirements and restrictions listed in the ICF and in the protocol.

•Tested positive SARS-CoV-2 infection (as determined by SARS-CoV-2 antigen test) at Screening.
•Determined in the interview prior to the study intervention to have a history of SARS-CoV-2 infection.
•Current history of poorly controlled cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disease that, in the opinion of the investigator or subinvestigator, would constitute a safety concern or confound data interpretation.
•Immunosuppressed (immunocompromised, having acquired immunodeficiency syndrome [AIDS], having received steroids and having received systemic immunosuppressants within 6 months prior to the first dose of study intervention, being treated for malignant tumors, being on other immunosuppressive therapy).
•Individuals considered to have hypersensitivity to any of the study interventions or components thereof, or drug or other allergy that, in the opinion of the investigator or subinvestigator, contraindicates participation in the study (except for pollinosis and atopic dermatitis).
•Participant has a contraindication to intramuscular(IM) injections or blood draws.

发起方

agata Tsutae